论文部分内容阅读
目的 :研究枸橼酸铋钾辅助常规三联药物方案治疗Hp感染阳性消化性溃疡的临床疗效。方法 :选择2015年1月~12月在我院接受治疗的Hp阳性的消化性溃疡患者140例。用随机数表法分为对照组(n=70)和实验组(n=70),对照组给予常规三联药物方案,实验组加用枸橼酸铋钾。结果 :实验组的总有效率为92.86%,对照组仅为80.00%,差异有统计学意义。实验组患者的Hp根除率为82.86%,对照组患者的Hp根除率为67.14%,差异有统计学意义。治疗后对照组和实验组患者的hs-CRP、IL-17和TNF-α水平均明显下降,实验组患者下降更为明显,差异有统计学意义。两组患者常见的不良反应包括便秘、恶心、黑便、腹泻和头晕,实验组患者的不良反应率更低。结论 :枸橼酸铋钾辅助常规三联药物方案可以提高Hp感染阳性消化性溃疡患者的临床疗效和Hp根除率,不良反应较低,安全性好。
Objective: To study the clinical efficacy of bismuth potassium citrate-assisted conventional triple drug regimen in the treatment of Hp-positive peptic ulcer. Methods: A total of 140 Hp-positive peptic ulcer patients treated in our hospital from January to December in 2015 were selected. The patients were divided into control group (n = 70) and experimental group (n = 70) by random number table. The control group was given conventional triple drug regimen. Bismuth potassium citrate was added to the experimental group. Results: The total effective rate of the experimental group was 92.86%, while the control group was only 80.00%, the difference was statistically significant. The Hp eradication rate was 82.86% in the experimental group and 67.14% in the control group, the difference was statistically significant. After treatment, the levels of hs-CRP, IL-17 and TNF-α in the control group and experimental group were significantly decreased, and the decline in the experimental group was more obvious, the difference was statistically significant. Common adverse reactions in both groups included constipation, nausea, melena, diarrhea and dizziness, with a lower adverse reaction rate in the experimental group. Conclusion: Bismuth potassium citrate adjuvant conventional triple drug regimen can improve the clinical efficacy and Hp eradication rate in patients with Hp-positive peptic ulcer with low adverse reactions and good safety.